Key facts
- This page summarizes Ivan Tornos's Form 4 filing for ZIMMER BIOMET HOLDINGS, INC. (ZBH).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 03 Mar 2022, 15:06.
Ivan Tornos - 01 Mar 2022 Form 4 Insider Report for ZIMMER BIOMET HOLDINGS, INC. (ZBH)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- ZBH
- Reported as of
- 01 Mar 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Mar 2022, 15:06:53 UTC
- Prior SEC filing
- 23 Feb 2022
- Next SEC filing
- 06 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matthew R. St. Louis, Attorney-in-Fact for Ivan Tornos (power of attorney previously filed)
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ivan Tornos filed Form 4 for ZIMMER BIOMET HOLDINGS, INC. (ZBH) on 03 Mar 2022.
Change
- Previous filing in this sequence was filed on 23 Feb 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ZBH
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +3,891
- Change %
- Price
- $0.000000
- Shares after
- 3,891
- Date
- 01 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,891
- Exercise price
- Footnotes
- F1, F2
ZBH
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +7,287
- Change %
- Price
- $0.000000
- Shares after
- 7,287
- Date
- 01 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,287
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.
Footnote F2
In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.